# A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Source: https://onco.cc/trials/nct03851640/  
OnCo record `nct03851640` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of HC-1119 in prostate cancer, run by Hinova Pharmaceuticals Inc., now recruiting.

## Summary

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). is a phase 3 interventional study registered as NCT03851640 by Hinova Pharmaceuticals Inc., with 417 participants planned, started 2019-04-12 and due to reach its primary completion in 2025-09. Interventions recorded: HC-1119 and placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03851640
- Phase: 3
- Setting: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Failed Treatments with Abiraterone Acetate and Docetaxel.
- Sponsor: Hinova Pharmaceuticals Inc.
- Enrolled: 417

## Sources

- ClinicalTrials.gov NCT03851640: https://clinicaltrials.gov/study/NCT03851640

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Hinova Pharmaceuticals](https://onco.cc/companies/hinova-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct03851640.json